Bevacizumab biosimilar - AryoGen Biopharma

Drug Profile

Bevacizumab biosimilar - AryoGen Biopharma

Alternative Names: AryoGen Farmad

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator AryoGen Biopharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer

Most Recent Events

  • 22 Aug 2016 Phase-III clinical trials in Colorectal cancer (Metastatic disease, First-line therapy, Combination therapy) in Iran (IV) (IRCT2015072517994N2)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top